New Ray Medicine International Holding Limited announced plans to adopt a third amended and restated set of Bye-Laws (the “New Bye-Laws”), replacing the current second amended and restated version.

The Board’s key objectives are: 1. Alignment with Hong Kong Stock Exchange requirements ahead of the Uncertificated Securities Market (USM) launch, enabling shareholders to hold and transfer shares in uncertificated form. 2. Miscellaneous housekeeping updates to reflect the latest Listing Rules.

Implementation timetable: • A special resolution will be tabled at the forthcoming annual general meeting (AGM). • The New Bye-Laws will become effective immediately after the AGM, subject to shareholder approval.

Procedural details: • A circular containing full text of the proposed amendments, AGM notice and proxy form will be issued in due course. • The Board confirmed that, after reasonable enquiry, no shareholder is required to abstain from voting on the resolution.

Board composition (as of 27 April 2026): • Executive Directors – Wang Qiuqin (Chairman), Chu Xueping, Zhou Wan. • Independent Non-Executive Directors – Leung Chi Kin, Li Sin Ming, Ivy, Sy Lai Yin, Sunny.

The proposed governance changes position New Ray Medicine to comply seamlessly with upcoming market infrastructure reforms while updating its corporate constitution to current regulatory standards.